June 25, 2021
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Key Points
Key points are not available for this paper at this time.
Abstract
In patients with type 2 diabetes, tirzepatide was noninferior and superior to semaglutide with respect to the mean change in the glycated hemoglobin level from baseline to 40 weeks. (Funded by Eli Lilly; SURPASS-2 ClinicalTrials.gov number, NCT03987919.).
Connected Papers
Building similarity graph...
Analyzing shared references across papers
Discussion
Loading...
Authors
J
Juan P. Frías
Royal Edinburgh Hospital
Melanie J. Davies
Royal Australian College of General Practitioners
Julio Rosenstock
General / Preventive / Lipids
Journals
New England Journal of Medicine
Actions
Institutions
University of Leicester
Eli Lilly (United States)
NIHR Leicester Biomedical Research Centre
References and Citations
Connected Papers
Building similarity graph...
Analyzing shared references across papers
Discussion
Loading...